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Abstract 
Background/Aims 
This paper reports data from a qualitative study of patient experiences of DNA testing 
and cascade screening for hypertrophic cardiomyopathy and long QT syndrome, cardiac 
conditions that place sufferers at risk of sudden death. The paper particularly focuses on 
potential impediments to testing and screening. 
Methods 
Semi-structured interviews were undertaken with a purposive sample of 27 people in the 
UK who had undergone testing.  
Results 
In the context of the uncertainties that can characterize experiences of these disorders, the 
majority of participants in this sample embraced testing and screening as a way of 
providing health information for themselves or their relatives (particularly children). 
There was nevertheless evidence of ambivalence about the value and impact of the DNA 
test information which could influence participants’ dispositions toward testing, and play 
into dilemmas about family communication. Other concerns arose in relation to 
communicating about these disorders, decisions to involve elderly relatives and pressures 
relating to family responsibility.  
Conclusion 
The evidence of ambivalence provides insight into why some people may be resistant to 
testing, screening and sharing information. The findings about communication processes 
indicate potential areas of concern for the cascading process.  
 
Keywords  
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Introduction 
 
This paper reports data collected from an exploratory, qualitative study of 27 people in 
the UK who had been DNA tested for a heritable cardiovascular condition that places 
them at risk of sudden cardiac death. Three key research questions were investigated: 
peoples’ experiences of (1) the disorders and their treatment, (2) the DNA testing 
process, and (3) sharing information in family groups. There is a growing body of work 
on patient experiences of such disorders (Anderson et al. 2008; Christiaans et al. 2009a,b; 
Cox et al.1997; Farnsworth et al. 2006; Hintsa et al. 2009; Ingles et al. 2008; Morgan et 
al. 2008). Previous studies show that DNA technologies are widely embraced, although 
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acknowledge the existence of ambivalence, reticence or resistance. This paper 
particularly focuses on interview data that highlight some of the issues that may impede 
the use of DNA testing as part of a cascade screening strategy. Such a strategy involves 
“systematically approaching relatives of patients affected by genetic disorders” (de Wert 
2005, p.397), and offering a predictive DNA test to those are potentially at-risk (based on 
information about a causal genetic mutation identified from a confirmed (index or 
proband) case). 
There are a number of cardiovascular conditions that place people at risk of 
sudden cardiac death; hypertrophic cardiomyopathy (HCM) and long QT syndrome 
(LQTs) are among the most well known (Chiang 2004; Maron 2002). These are distinct 
and different kinds of cardiac disorders, yet there are sufficient similarities in their 
presentation to legitimate examining them jointly in a study of patient experience. 
Symptoms of both conditions often become evident in teenagers and young adults, and as 
fatalities can result the first time the disorders present themselves there are tragic stories 
of unforeseen deaths. Their incidence usually shows a familial pattern, and their heritable 
forms are usually autosomal dominant (Chiang 2004; Maron 2002). To date, HCM has 
been connected to mutations in at least thirteen different genes (Alcalai et al. 2008; Lind 
et al. 2006) and mutations in at least twelve different genes have been related to LQTs 
(Hedley et al. 2009). When it is useful to refer to HCM and LQTs together in this paper, 
they will be termed inherited cardiac conditions. 
Importantly, there can be a degree of uncertainty surrounding diagnosis, prognosis 
and therapy (Michels et al. 2007). These are disorders which display phenotypic 
heterogeneity, with a range of symptoms (including “none”) (Ingles et al. 2005; Keren et 
al. 2008; Vincent 1998). Symptoms such as arrhythmias and fainting can be attributed to 
many causes, and heart muscles can become thickened due to other factors. Clinical 
examinations using echocardiograms, electrocardiograms (ECGs) and 24-hour Holter 
Monitors can result in complex “borderline” cases (Crotti et al. 2008). Interventions to 
reduce symptoms and risk of dying include implantable defibrillators (in high-risk cases), 
drug therapies, lifestyle advice and routine clinical monitoring (Chiang 2004; Maron 
2002). Nevertheless, some common interventions can themselves be sources of 
uncertainty in patient experiences (Andersen et al. 2008; Farnsworth et al. 2006; Henriks 
et al. 2005; Maron et al. 2004; Sola and Bostick 2005). 
Research on patient experience of inherited cardiac conditions highlights worry 
and uncertainty. With respect to LQTs, Farnsworth et al. (2006, p. 285-6) report sources 
of uncertainty and anxiety to be not only the diagnosis of a “potentially lethal” condition 
but also the “vast spectrum of clinical presentation” and the “stressors” relating to their 
“treatment and management.” In Anderson et al.’s (2008, p. 492) study of coping with the 
disorder, uncertainties included worries about not knowing “what was happening”, 
difficulties in interpreting physical feelings and the potential loss of control. With respect 
to HCM, Cox et al. (1997, p. 187) conclude that worry is a “widespread problem, and 
possibly one that is inherent in the condition. For despite reassurance and education, 
uncertainties about prognosis inevitably persist.” It has been argued that those living with 
a familial risk of HCM, but without symptoms, may face so much uncertainty that even a 
positive DNA test has the potential to restore a sense of control or provide reassurance 
(Christiaans et al. 2009a), as has been recorded in relation to DNA tests for other 
disorders (Marteau and Mitchie 1995). Another area of significant concern for those at 
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risk of inherited cardiac conditions are issues relating to children (and grandchildren) and 
reproduction (Anderson et al. 2008; Charron et al. 2002; Farnsworth et al. 2006; Hendriks 
et al. 2005; van Langen et al. 2004, Yu et al. 1997). It has been shown with respect to 
HCM, however, that worry can be alleviated by attending specialized cardiac genetics 
clinics (Ingles et al. 2008), and this has also been recommended for those at risk of LQTs 
(Anderson et al. 2008). 
The effectiveness of molecular genetic testing and cascade screening for inherited 
cardiac conditions is under discussion (Charron et al. 2002; Christiaans et al. 2008; 
Langen et al. 2004; Michels et al. 2007; van Yu et al. 1997). Pinpointing the causal 
genetic mutation in probands can confirm a diagnosis and may influence their clinical 
care. This knowledge can then also be used to screen relatives with a greater degree of 
certainty than clinical examinations alone (Yu et al. 1997), allowing for the discharge of 
those without a mutation (people who would otherwise have been treated as at risk) and 
the identification of clinically unaffected but genetically at risk individuals (with the 
potential for preventing sudden cardiac death). However, as the genes involved in these 
disorders have variable expressivity and penetrance (Vincent 1998; Yu et al. 1997) being 
diagnosed as “genetically at risk” does not necessarily provide insights into variability in 
phenotype and symptoms (Farnsworth et al. 2006). Also, the “predict and prevent” 
strategy relies on information about the disorder and the possible inventions being 
communicated within families – a responsibility which usually falls to the proband. 
These issues of continuing uncertainty and communication will be addressed in the 
subsequent discussion.  
 
Methods 
This research was affiliated with a program of work developing molecular genetic testing 
and cascade screening for HCM and LQTs in the UK, conducted by the Inherited Heart 
Disease service in Oxford as part of the Genetics Knowledge Park programme. This 
exploratory qualitative study aimed to investigate the experiences of people who had 
been offered testing. A qualitative methodology, using semi-structured interviews, was 
the most appropriate approach for gaining in-depth information.  
 
Sample 
 
Twenty-seven interviewees were selected purposively (Ritchie et al. 2003) on the primary 
criterion that they had undergone a DNA test for an inherited cardiac condition, with 
diversity sought on differences in the condition (HCM/ LQTs), route into testing 
(proband/ cascaded) and test result (positive/ negative). The participants were “recruited” 
via their medical practitioner (cardiac specialist, clinical geneticist or genetic counselor), 
following an ethics protocol approved by a Multi-centre Research Ethics Committee 
(MREC) which also specified processes for data collection and storage. Twenty four 
information packs sent from the clinic where the study originated generated fifteen 
participants (the reasons why nine people did not volunteer are unknown). To gain 
sufficient participants to ensure diversity in the sample, information packs were also 
distributed to seventeen other UK hospitals that had requested DNA testing during the 
study time-frame (it is not known how many practitioners gave information packs to 
patients, or how many patients refused the invitation to take part and why). All potential 
An author-created final version of article published in “Journal of Genetic Counseling”, 2010, 19(6): 630-39. 
 4
participants who expressed an interest in taking part in the study were interviewed, 
resulting in an additional twelve participants from seven locations. Table 1 (Participant 
Characteristics) and its accompanying footnotes describe some key variations within the 
sample: condition (14 HCM, 13 LQTs), clinical status (20 treated as affected, 7 treated as 
unaffected), DNA result (17 positive, 7 negative, 3 no known mutation) and test status 
(15 proband, 9 cascade, 3 research).  
 
Interview protocol and procedures 
 
Data collection took place during 2005-06. Interviews were conducted in a setting chosen 
by the participant (usually their home) and were preceded by MREC agreed informed 
consent processes. All of the interviews were conducted face-to-face by the author, a 
trained social science researcher with 10+ years experience. Two interviews included 
multiple participants from the same family group (one involved two people, and one 
involved three). The median interview length was 49 minutes (Range: 27 minutes to  84 
minutes).  
Interviews were conducted using a topic guide that was checked with an advisory 
panel of academics, a cardiac genetics counselor and a patient support group organizer to 
ensure that it was appropriate (See Appendix). The interview guide was structured around 
five topics: experiences of the condition; the process of DNA testing; sharing information 
in families; benefits and drawbacks of testing and screening and the provision of 
information. This guide was used flexibly and participants were encouraged to discuss 
issues that had the greatest significance to them.  
 
Data Analysis 
 
Interviews were audio-recorded and fully transcribed (and then cross-checked to ensure 
accuracy). Data analysis was developed by the author using an “analytical hierarchy” 
approach which begins with processes of coding, sorting and summarizing and links 
these to higher levels of analytical abstraction such as establishing typologies, detecting 
associations and developing explanations (Spencer et al. 2003). Transcripts were closely 
read and annotated to develop codes to sub-divide and categorize the data (Dey 1993), 
with sub-codes developed inductively from within the topics in the interview guide. 
Initial codes were developed and iteratively revised using the data from the first fifteen 
participants that had been imported into QSR NVivo qualitative data analysis software 
(Bazeley and Richards 2000). An interim “thematic analysis” (Gomm 2004) was 
developed to consolidate the coding frame and provide an analytical framework for 
exploring the areas of commonality and divergence within the dataset (this analysis was 
read and validated by a cardiac genetics counselor). Each additional transcript was then 
analysed to check consistency with (or difference from) the findings therein. The cross-
sectional analysis presented here draws attention to commonalities and differences across 
the sample as a whole (Spencer et al. 2003).  
 
Results 
Psycho-social responses to test results 
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Before considering issues of ambivalence and communication, some findings relating to 
predictive DNA tests should be noted. Two of the nine participants tested in a cascade 
screen were DNA positive. One participant (R23), who reported no history of symptoms, 
appeared outwardly unconcerned by her positive test result. The explanation for this 
somewhat surprising reaction appeared to be that she had children who were clinically 
affected and receiving treatment, and claimed that she had thus expected a positive result. 
The other participant, however, explained that he was “a bit shocked really” and showed 
some evidence of having subsequent feelings of health anxiety and guilt relating to other 
members of his family;  “when I found out I thought: ‘oh, it’s me that’s causing all this 
trouble’” (HCM, treated as unaffected, DNA positive, Cascade: R06).  
Five of the seven cascaded participants who were DNA negative were clinically 
unaffected, and thus the “all clear” result was reported as largely expected (although a 
sense of relief was sometimes evident). The other two participants who received negative 
DNA results in a cascade screen had been treated as if they were affected by an inherited 
cardiac condition, and both reported a sense of shock at their result. One of these 
participants also exhibited distress (anger and regret) about the extent to which her (now 
over-turned) diagnosis had impacted life experiences:  
 
So it was yeah quite a shocker, in fact very, very shocking.  So I’d spent 20 years 
on medication and living, potentially, I could have lived a life you know in cotton 
wool so to speak” (LQTs, treated as affected, DNA negative, Cascade: R13).  
 
The other participant appeared more sanguine, although notably she still perceived 
herself as unwell, with her symptoms having a different cause: “I’ve got the condition but 
I haven’t got the gene, my condition is caused by high blood pressure” (HCM, treated as 
affected, DNA negative, Cascade: R05). 
 
 Viewpoints on DNA testing 
There were broadly two types of response to the potential of DNA testing and screening. 
One outlook was to embrace the potential for reducing uncertainties This response was 
usually accompanied by a belief that the outcomes of a DNA test could give greater 
certainty in diagnosis (participants used terminology such as “definite”, “absolute”, 
“certain” or “conclusive”). The desire to predict who was at risk was sometimes 
accompanied by a sense of urgency in relation to younger relatives; for example, one 
participant pressed to get her young children DNA tested because she “wanted to know 
now” (HCM, treated as affected, DNA positive, Research: R03). This welcoming 
response to the potential of DNA technologies was the most common attitude in this 
sample of participants. 
However, a notable minority of participants (6/27) - while not entirely against 
DNA tests - expressed concerns about them, or the benefits of knowing their results. It is 
possible to identify five (potentially interlinking) sources of ambivalence, which together 
had the potential to influence attitudes to testing and screening. These are reported below 
to demonstrate the potential range of patient concerns and as such, no judgement is 
offered by the author about the clinical “accuracy” of the participants’ views, and no 
comment can be made (given the sampling strategy) about how widespread these 
perceptions might be.  
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The first concern is that a “negative” DNA result in a symptomatic patient was 
not necessarily an “all clear,” and that this may add to experiences of uncertainty. One 
participant, whose echocardiogram had revealed a “possible thickening of the heart 
muscle” but who knew of no experiences of the disorder in her family, described the 
results of a DNA test that she had taken in an attempt to confirm her diagnosis: 
 
[…] they tested three genes and they all came back negative. But as [the genetic 
counselor] said, it doesn’t mean that I haven’t got it. [..] because, I mean it was 
made very clear that if the results all come back negative it’s, you know, it’s 
maybe. I don’t even think they said it’s inching towards having not got it. (HCM, 
treated as affected, No known mutation, Proband: R27) 
 
The participant reported that the potential for an inconclusive outcome had been 
explained to her. Nevertheless, her admission that “I’d like to have a concrete yes or no 
rather than a ‘we don’t know, but live like you’ve got it’” indicated her continuing 
dissatisfaction. Indeed she reported: “the main problem is because they still haven’t told 
me definitely that I’ve got [HCM].” Despite her awareness of this scenario, the 
“negative” DNA test result was a disappointment because it failed to remove uncertainty. 
A second concern was the finality of DNA test results. This next participant was 
asymptomatic, but had relatives diagnosed with LQTs and had experienced sudden 
cardiac death in his family. He reported that he was searching for a conclusive diagnosis 
and, when asked, revealed a degree of hesitancy about his (negative) DNA result being 
the end of the matter: 
 
R10 […] nobody was prepared to say I haven’t got it. Along the line they were 
all saying less likely, no symptoms, less likely, no symptoms, not conclusive you 
know, all the way along. So when this thing [the DNA test] came up at Oxford, 
seemingly conclusive, I said ‘we’ll have a bit of that.’ 
 
AS Okay, you say seemingly conclusive? 
 
R10 Well, you know, until next time somebody says: ‘well, actually it’s not 
conclusive’ and then we’ll do some …, another test. (LQTs, treated as unaffected, 
DNA negative, Cascade: R10).  
 
Interpreted at face-value, this apparent expression of cynicism was related to the inherent 
uncertainty and evolving nature of medical knowledge and testing (it is unclear whether 
this is cynicism in general, or specific to LQTs). An alternative or supplementary 
interpretation, however, is that despite a negative DNA result the participant was 
revealing underlying feelings of denial (expressing doubt because he still fears that he has 
LQTs), or even “survivor guilt” (expressing doubt as a mechanism for coming to terms 
with the knowledge of not having LQTs, while his relatives do).   
The third source of ambivalence regarding DNA testing concerned the impact of a 
positive DNA diagnosis on quality of life. The following account is from the same 
participant quoted previously:  
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You get to a stage where you’re thirty-eight years old, which is my age, and you 
think okay it hasn’t bothered me up to now and do I want to reduce the quality of 
my life in the future by finding out and possibly having to take beta blockers [..]  I 
don’t want to, didn’t want to go on beta blockers because you know two of my 
[siblings] are on them, they’ve both put on a lot of weight, they weren’t able to do 
the sport things that they were able to, it’s a whole change of life and so I didn’t 
want that. (LQTs, treated as unaffected, DNA negative, Cascade: R10) 
 
His decision to take a DNA test, at least as he reviewed it in retrospect following a 
negative DNA result, was framed by two appraisals. The first was a risk assessment 
based on symptoms and age (this participant perceived that he might be less at-risk 
because of he was thirty-eight and asymptomatic, reflecting a common view that LQTs 
often affects younger people). The second weighed any potential benefits of “finding out” 
(i.e., a positive DNA diagnosis) against fears that potential treatments may affect his 
“quality of life” (represented by weight and lifestyle).  
Discussions with parents about DNA testing their children revealed two further 
interrelated sources of ambivalence. One was that a positive DNA test did not give 
certain knowledge about prognosis, and this was linked to a second worry that knowing 
one was at risk of sudden cardiac death could be an emotional or psychological burden. 
The following participant reflected on the different experiences of two of his siblings 
who had died (only one of whom had known that he was at risk): 
 
With the benefit of hindsight [..] it might well have been better if he hadn’t known 
because he’d have just got on with his life. You know for [my sister] of course it 
was tragic that she didn’t have…, but she didn’t know anything about it, she lived 
a fully active life until suddenly something happened but [my brother] knew about 
it for 7 years, the most informed 7 years of his life knowing that this was hanging 
over him as a threat and the advantage of knowing it was there didn’t translate [..] 
I don’t think that was a great improvement to his life. (HCM, treated as affected, 
DNA positive, Proband: R08) 
 
This participant, unconvinced of the benefits of knowing (because this had not improved 
his brother’s life, or prevented his death), concluded that his children’s DNA test results 
were not the “real answer,” as he still did not know full implications. Another participant 
similarly reported ambivalence about getting his children DNA tested for HCM:  
 
I’ve got very mixed thoughts about that because I think, you know, if it is possible 
to know about these conditions at such a young age, I think that could really have 
a hugely life changing impact. [..] And so if my son is given that definite label, 
you know at the age of twelve or whatever, then I’m sure it’s definitely going to 
have an impact on him. I mean one of the things that is said is that if children 
have got this diagnosis, they ought to be directed away from very competitive 
sports and things like that. But you know I think if you have enough of a family 
history and a suspicious enough background then you can probably direct your 
children away from those things anyway without giving them the label, because at 
the end of the day we don’t have a …, you see one of the things that is frustrating 
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about this condition is that there’s no definite treatment that’s going to prevent the 
sudden death and there’s no absolute way of picking out who will get the sudden 
death. (HCM, treated as affected, DNA positive, Proband: R11) 
 
This participant felt that not only did a positive DNA test fail to provide more certain 
knowledge about disease prognosis or treatment, but also it carried with it a label that was 
a burden in everyday life (in insurance and other bureaucratic realms, and also as an 
emotional and psychological influence). It is notable that, in this sample and from the 
point of view of some participants, concerns about the lack of treatment options pertained 
to HCM rather than LQTs. 
 
Viewpoints on family communications 
The range of information that interviewees reported having shared with others in their 
family included details about: the disorder, DNA tests and the processes of cascade 
screening. Experiences of sharing information in family groups were variable. Some 
participants considered the process to be unproblematic: they thought they knew who to 
contact, how to contact them, what they needed to say and were confident that they could 
provide the necessary information. (It should be held open to question whether 
participants’ ideas about these areas necessarily coincide with those of practitioners). 
Data analysis also revealed a range of difficulties in communication, including 
“knowledge” issues (knowing which family members could have inherited the gene 
alteration, and explaining the medical / genetic aspects to someone else) and loss of 
contact for either mundane or complex/ sensitive reasons (e.g., not having a contact 
address or phone number, or not wanting to speak due to previous disagreements).  
The following extract, from a participant who reported a particularly difficult 
experience, illustrates how a variety of factors can become interlinked in decisions about 
sharing information: 
 
R19 The biggest issues that have come up are people [health practitioners] 
saying to us that you should be telling certain members of the family and certain 
members of the family saying, you know; ‘no, don’t bother people with it’  […] 
My mum’s side of the family didn’t want me to get in contact with that side of the 
family.  I sort of think, well why I am worrying with it?  I don’t know, I don’t 
know what to do.  We’re still trying to decide on whether to contact them.  […] 
But it’s very difficult going to strangers and saying ‘Look sorry to tell you this, 
you might have this condition, do you want to know?’ when they could just go 
through, well they could get on quite happily with their lives basically. […] I just 
feel like, you know, if I could just tell them, that you can have the test, then it 
would just be nothing to do with me anymore and I could just not…, you know, 
it’s nothing to do with me anymore.  I don’t know. Mum just doesn’t think I 
should get involved. 
 
AS Right, and what does your husband think? 
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R19 He thinks, he thinks yes, we should do it, definitely; because of the 
children, yeah their children. (LQTs, treated as affected, DNA positive, Proband: 
R19) 
 
The dilemma expressed here reveals the intersection between: a “complex” and 
geographically dispersed family network; weak relationships with some family members 
(some of who she did not know, or know how to contact); competing advice or pressures 
(from health professionals and kin including “blood” relatives and spouse); personal guilt 
and anxiety; and, the difficulties of communicating information about the condition.  
Of the difficulties in communication that were reported, those that were more 
specific to inherited cardiac conditions were rooted in the sudden and extreme nature of 
the health threat to other family members, particularly children. While for most this was a 
motivation to communicate, in some instances it was experienced as a burden of guilt and 
anxiety (particularly where there were other barriers to communication). The difficulties 
involved in speaking with relatives about inherited cardiac conditions were: how to start 
the conversation about being at risk of sudden death; how to tell people they (or their 
children) would have to stop playing sports or doing strenuous exercise; the worry that 
they (or the recipient) would find it an emotional or stressful conversation, or that the 
recipient might not want to know, particularly because the knowledge could be a burden. 
This last issue is encapsulated by the question that Participant 19 (quoted earlier) 
imagines she will have to pose to her relatives: “do you want to know?”, to which she 
then adds “when they could just go through, well they could get on quite happily with 
their lives basically.” As reported in the previous section, there is a possibility that some 
people might not want to know – that they might think they are better off not knowing. 
The above extract suggests that people who are ambivalent about the benefits of the 
knowledge can worry that they are going to force unwanted knowledge on others. 
Three participants voiced disquiet about involving their elderly parents in 
screening, or they had already declined to involve them. They offered a number of 
reasons. First, they did not want to worry them with information about a heart problem, 
particularly where they had other health concerns. Second, it was suggested that a 
diagnosis of the condition would not be directly beneficial to people in the later stages of 
life. Some participants thought that as these disorders most often develop in young 
people, elderly parents were less likely to be at risk. Third, there was also a desire to 
protect parents from the potential guilt of passing on a “faulty” gene. These decisions by 
“adult children” to protect their parents could pose a barrier for taking cascade screening 
beyond first degree relatives (as will be discussed in the following section). 
There was also evidence of pressure from relatives to get other people in the 
family tested, based on fears or anxieties about the disorders. For example, one person 
reported actively “persuading” a sibling to undergo DNA testing by arguing that she had 
a duty to protect the younger generations of her family. She explained how she had 
convinced her sister of the “logic” of cascade screening by persuading her that if she took 
a DNA test and was clear, she could then protect her children and grandchildren from 
ever having to worry about the disorder. In another example, a participant had 
complained that her parents had applied strong pressure on her to get tested, and had only 
realised afterward “that all this pressure that they were putting on me, was probably fear 
in them that I may have it, and their granddaughter” (HCM, treated as unaffected, DNA 
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negative, Cascade: R25). These instances reveal that cascade screening for inherited 
cardiac conditions can open up feelings of responsibility about health to the wider family 
unit, with some family members using the interests of younger generations to exert 
pressure on decision-makers.  
 
Discussion 
For the participants in this study, DNA testing and cascade screening were commonly 
embraced as ways of reducing uncertainties in diagnosis. The ambivalent responses 
(albeit in a small proportion of participants) were a main focus of the findings as they 
provide an insight into the challenges that might face those promoting or implementing 
DNA testing and cascade screening. Anderson et al. (2008, p. 496) note that we “can only 
speculate about the reasons why some individuals do not want to be tested […]”, but in 
the absence of studies of such individuals, the evidence presented in the research study 
can play a role. The findings regarding ambivalence reveal the kinds of concerns held by 
people who were faced by choices regarding DNA testing, and included the perceptions 
that it might be better not to have to live with the knowledge that you are at risk of 
sudden cardiac death, that a positive DNA result might not relieve uncertainties about 
personal risks, and that testing might actually have negative social and psychological 
consequences of its own. These sources of ambivalence may (even if only in part) 
contribute to understanding other evidence of reticence, such as relatives not welcoming 
information about their genetic status for LQTs (Andersen et al. 2008), reports of a 
limited uptake for genetic counselling for HCM (Christiaans et al. 2008), and a small 
minority of people who had been DNA tested for HCM admitting they would rather have 
not known (Christiaans et al. 2009b).  
The findings of the present study concerning family communications also have 
implications for providing services for DNA testing and cascade screening. Perceptions 
about disease severity, interventions and the certainty offered by testing, were influential 
factors affecting the sharing of information in families, as they are in previous studies 
(Wilson et al. 2004). In the context of inherited cardiac conditions (at least in this sample 
of participants), the risks of sudden death in the young contribute not only a particular 
sense of compulsion and urgency for sharing information, but also a potential for anxiety 
and guilt, particularly where there were perceived barriers to communication. These 
barriers were reminiscent of other studies (Gaff et al. 2007; Wilson et al. 2004) but were 
specific to inherited cardiac conditions in so far as they related to the challenges of 
talking about sudden death, and the effects of a diagnosis on lifestyle. 
It is know that non-disclosure dilemmas can stem from concerns about causing 
harm, distress or alarm to relatives (Clarke et al. 2005; Keenan et al. 2005), but a notable 
aspect of this study is evidence suggesting that a lack of conviction about sharing 
information could relate to an ambivalent attitude toward the “benefits” of the 
knowledge. Underlying this ambivalence was the dilemma of whether knowing that you 
are at risk of sudden death was a good or a bad thing. Where participants thought that 
treatments were available and effective, the common refrain could be paraphrased as: 
“Why wouldn’t you want to know?” Where participants were more skeptical about 
interventions, there was ambivalence about the value of DNA tests which could impact 
on thinking about getting tested, getting children tested or passing on information to other 
family members.  
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In this study there was a notable inversion of the usual pattern of parental-child 
decision-making (Gaff et al. 2007; Keenan et al. 2005), as some children (albeit adult 
children) were taking responsibility for decisions about their parents’ involvement in 
testing. Judgements about obligations and the vulnerability of the recipients with respect 
to information were evident in this sample, as part of the well-known disclosure dilemma: 
Is the emotional harm of disclosure lesser than the medical benefit (Gaff et al. 2007; 
Wilson et al. 2004)? Some participants thought that the tangible health benefits for some 
vulnerable older relatives were not particularly clear cut, weakening the imperative for 
sharing the information with them. These results could have implications for cascade 
screening for inherited cardiac conditions, as, in some instances, testing elderly family 
members can contribute to assessing the risks faced by people in the extended family 
group. 
A similar cost-benefit analysis of the value of the information may also deter 
some people from a DNA test. In this study there was evidence of reticence, persuasion 
and resistance, sometimes linked to a perceived lack of “personal benefit” from DNA 
testing. The primary motivation for DNA testing for an inherited cardiac condition is to 
gain health information relevant to oneself or to one’s children or family, and it has been 
reported elsewhere that there can be family pressures to be involved in cascade screening, 
with elderly people often citing their (grand)children as the reason for testing (Christiaans 
et al. 2009b). The findings herein underline that, for some people, choosing (or refusing) 
to have a DNA test for an inherited cardiac condition (and/or to be involved in sharing 
information) could rest on perceptions and pressures concerning family responsibility 
rather than on overt personal health benefits.  
 
Limitations of the Study.  
 
The heterogeneity within the sample is notable and may influence experiences. While 
there were no consistent divergences among different “kinds” of participants (i.e., 
according to the characteristics in Table 1) in the data analysis, such differences could be 
masked within a small sample. Other potentially important sources of variation include 
age (this information was not collected), symptoms and experiences of the disorders (in 
the individual and the family group), the time that had elapsed since testing and the 
influence of testing and counselling processes and practices (participants here received 
care in various locations, at different times and had different routes into testing). The 
extent of variation in this research is not unusual for an exploratory qualitative study, and 
actually provides an important benefit by helping to reveal a wider range of experiences 
than in a more homogenous sample.  
A second limitation is potential sampling biases: health practitioners who were 
well-disposed toward a DNA testing service chose which (if any) of their patients 
received information packs; and, the interviewees “self-selected.” These constraints, 
common in qualitative research, were in this instance a consequence of requiring 
“gatekeepers” to facilitate access to a small number of potential participants. It could be 
noted, however, that these biases could potentially work in contradictory ways, leading 
not only to a high representation of “positive” views of testing but also for interviews 
becoming a platform for voicing dissatisfaction about treatment. Also, a number of 
participants were from the same families and therefore may share similar views of or 
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experiences with the disorders and genetic testing. While a purposive sampling technique 
ensured relevant data were collected, no claims are made for the representativeness of the 
sample.  
 
Research Recommendations 
 
Further research is needed (if possible using more generalizable sampling techniques) to 
establish the frequency of the viewpoints reported herein, to assess whether they are more 
or less likely to be expressed by different “types” of participants, and to determine 
whether they have any real effect on the uptake of, or satisfaction with, health service 
provisions. Research could also investigate clinical interventions and counseling 
strategies designed to address such concerns. As the ambivalence reported in this study 
represents the experience of people who underwent testing despite their misgivings, it is 
necessary to investigate the extent to which these reservations match those of individuals 
who resist involvement in testing (although accessing potential participants is recognized 
to be a significant challenge). 
 
 Implications for practice  
 
Although the experiences reported herein are not claimed to be generalizable to the wider 
patient population, they could alert health practitioners to areas for further consideration. 
First, the positive reception to DNA testing is arguably related to its potential to alleviate 
uncertainties. Nevertheless, DNA tests do not necessarily meet all desires for certainty, 
and this disjuncture may be either a source of ambivalence in decision-making (to 
undertake testing or share information in families), and/or a potential source for 
disappointment post-results. Second, other fruitful grounds on which to investigate 
reticence about, or resistance to, testing and sharing information could be: perceptions 
about the social, psychological and lifestyle effects of a diagnosis and skepticism about 
interventions (and the overarching issue of how to cope with living with a threat of 
sudden death).  
Third, facilitating a cascade screen in a family group may require going beyond 
individuals’ instrumental health concerns to confront questions of family responsibility 
(which have the potential to raise ethical dilemmas about the duty of care and the duty to 
warn). On a practical level, a cascade screen may be supported by finding the most 
appropriate ways of supporting patients in their discussions with their relatives. Fourth, 
there is potential for those involved in predictive testing for inherited cardiac conditions 
to experience shock and distress at negative results as well as guilt and health anxiety in 
relation to positive results. Also, if those who are DNA negative still perceive themselves 
as unwell, any shift in care patterns (i.e., outside of specialist genetics/cardiology) needs 
to be handled sensitively. Fifth, it is possible that the sense of urgency that accompanies 
the threat of sudden cardiac death and concern for others (often young people) might lead 
to ongoing anxiety during the testing and screening process, and a desire for fast service 
provision. 
These findings could help to guide practitioners as they develop appropriate forms 
of anticipatory guidance regarding information provision and genetic counseling. Such 
guidance might include considering the extent and value of information provided by a 
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DNA test (particularly in connection to perceptions of uncertainty); and, reflecting upon 
the implications that different test results may have for treating the disorders, and for 
living and coping with them. Cascade screening processes could be facilitated by 
identifying appropriate, effective and sensitive mechanisms for sharing information in 
families, and developing the means for supporting patients with communication. For 
example, practitioners could provide patients with a letter to share with their family 
members to document the diagnosis, symptoms, risk of cardiac events and potential for 
testing. 
 
Conclusion 
 
DNA testing and cascade screening is welcomed by many of those living in families at 
risk of inherited cardiac conditions as a means for reducing the uncertainties associated 
with these conditions. The evidence of ambivalence, however, shows that some important 
uncertainties can remain which may affect peoples’ dispositions toward testing and 
screening. Potential impediments to cascade screening also arose in relation to issues of 
communication and family responsibility. The present findings could provide health 
practitioners with insight into why some people at risk of inherited cardiac conditions 
may be resistant to testing, screening and sharing information. Further investigations are 
necessary to test these exploratory findings using a more generalizable study design that 
considers the influence of different clinical protocols on patient experience and/or 
explores the views of people who have refused to be involved in testing and screening.   
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APPENDIX: INTERVIEW GUIDE 
 
Theme A. Experiences of the Condition and Treatment 
 
Personal and family history of the disorder 
What has happened during medical care? 
 
Theme B. DNA Testing 
 
Why offered the DNA test? 
What were the results? 
Key reasons for having the test? 
Any difficulties in making the choice? 
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Effects of DNA test on how they think about the condition. 
 
Theme C. Family Communication 
 
Were they the first person to have a DNA test? Who else has had a test? 
Did they contact other family members about the test? Who and why? 
Were there family members they didn’t contact? Who and why? 
Difficulties in the process of communicating with relatives. 
Amount of (and preferred) support/ advice/ information from the medical team. 
 
Theme D. Benefits and Drawbacks 
 
The positive and negative outcomes of DNA testing for them and their family. 
Has participation in DNA testing left any lingering concerns or outstanding 
problems? 
 
Theme E. Information Provision 
 
What information was given about the implications of the results of a DNA test?  
Was this given at appropriate times, and were there opportunities to discuss 
issues, concerns or problems?  
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Table 1: Participant characteristics 
Participant ID Disorder Clinical Status1 DNA test2 Test Status3 
R01 HCM affected positive research 
R02 HCM affected positive research 
R03 HCM affected positive research 
R04 HCM affected positive proband 
R05 HCM affected negative cascade 
R06 HCM unaffected positive cascade 
R07 HCM affected positive proband 
R08 HCM affected positive proband 
R09 LQT affected positive proband 
R10 LQT unaffected negative cascade 
R11 HCM affected positive proband 
R12 HCM affected positive proband 
R13 LQT affected negative cascade 
R14 HCM affected no known mutation proband 
R15 LQT unaffected negative cascade 
R16 LQT affected positive proband 
R17 LQT affected positive proband 
R18 LQT affected positive proband 
R19 LQT affected positive proband 
R20 LQT unaffected negative cascade 
R21 LQT unaffected negative cascade 
R22 LQT affected positive proband 
R23 LQT unaffected positive cascade 
R24 LQT affected positive proband 
R25 HCM unaffected negative cascade 
R26 HCM affected no known mutation proband 
R27 HCM affected no known mutation proband 
 
                                                 
1 Classifying participants “clinical status” as affected or unaffected was somewhat problematic; this was 
based on participants’ (sometimes unclear) accounts, not clinical records, and as previously noted, these are 
disorders in which there are “grey” areas. Those who reported being treated by health practitioners as at-
risk were classified as affected (including two who took part in cascade screening and subsequently had 
negative DNA tests [R05, R13]). To recognize this potential ambiguity, the phrase “treated as affected/ 
unaffected” was used when labelling responses in this article 
2 The three DNA results of “no known mutation” were patients who were having a test to confirm a 
diagnosis, but who had not had a positive match against the three common genetic variants included in the 
screen (meaning that further research on their DNA would be required to confirm a diagnosis or facilitate a 
cascade screen for their family) 
3 The “research” test status denotes that three participants’ DNA tests were part of historic HCM family 
research studies that were unrelated to the program of work that gave rise to this study. Despite this, the 
label “proband” was used for the purpose of classifying their “test status” in this article  
